Department of Health Services Research, Maastricht University, Maastricht, The Netherlands.
CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands.
Diabet Med. 2020 Oct;37(10):1759-1765. doi: 10.1111/dme.14285. Epub 2020 Mar 18.
To estimate the societal costs and quality of life of people with type 2 diabetes and to compare these results with those of people with normal glucose tolerance or prediabetes.
Data from 2915 individuals from the population-based Maastricht Study were included. Costs were assessed through a resource-use questionnaire completed by the participants; cost prices were based on Dutch costing guidelines. Quality of life was expressed in utilities using the Dutch EuroQol 5D-3L questionnaire and the SF-36 health survey. Based on normal fasting glucose and 2-h plasma glucose values, participants were classified into three groups: normal glucose tolerance (n = 1701); prediabetes (n = 446); or type 2 diabetes (n = 768).
Participants with type 2 diabetes had on average 2.2 times higher societal costs than those with normal glucose tolerance (€3,006 and €1,377 per 6 months, respectively) and had lower utilities (0.77 and 0.81, respectively). No significant differences were found between participants with normal glucose tolerance and those with prediabetes. Subgroup analyses showed that higher age, being female and having two or more diabetes-related complications resulted in higher costs (P < 0.05) and lower utilities.
This study showed that people with type 2 diabetes have substantially higher societal costs and lower quality of life than people with normal glucose tolerance. The results provide important input for future model-based economic evaluations and for policy decision-making.
评估 2 型糖尿病患者的社会成本和生活质量,并将这些结果与血糖正常或糖尿病前期患者的结果进行比较。
本研究纳入了基于人群的马斯特里赫特研究中的 2915 名个体。通过参与者完成的资源使用问卷评估成本;成本价格基于荷兰成本指南。使用荷兰 EuroQol 5D-3L 问卷和 SF-36 健康调查,以效用表示生活质量。根据正常空腹血糖和 2 小时血浆葡萄糖值,参与者被分为三组:血糖正常(n=1701);糖尿病前期(n=446);或 2 型糖尿病(n=768)。
与血糖正常者相比,2 型糖尿病患者的社会成本平均高出 2.2 倍(分别为 6 个月 3006 欧元和 1377 欧元),效用更低(分别为 0.77 和 0.81)。血糖正常者和糖尿病前期患者之间无显著差异。亚组分析显示,年龄较大、女性以及有两种或更多糖尿病相关并发症会导致更高的成本(P<0.05)和更低的效用。
本研究表明,2 型糖尿病患者的社会成本和生活质量明显低于血糖正常者。研究结果为未来基于模型的经济评估和政策决策提供了重要依据。